Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
Status:
Not yet recruiting
Trial end date:
2026-11-02
Target enrollment:
Participant gender:
Summary
Background:
Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths in
the airways. These growths come back when removed; some people may need 2 or more surgeries
per year to keep their airways clear. Better treatments are needed.
Objective:
To see if a drug called bevacizumab can reduce the number of surgeries needed in people with
RRP.
Eligibility:
People aged 18 and older with recurrent RRP; they must need surgery to remove the growths in
their airways.
Design:
Participants will be screened. Their ability to breathe and speak will be evaluated. They
will have an endoscopy: a flexible tube with a light and camera will be inserted into their
nose and throat. They will have a test of their heart function and imaging scans of their
chest.
Participants will have surgery to remove the growths in their airways.
Bevacizumab is given through a small tube placed in a vein in the arm. After the surgery,
participants will receive 11 doses of this drug: every 3 weeks for 3 doses, and then every 6
weeks for 8 more doses. They will come to the clinic for each dose; each visit will be about
8 hours.
Tissue samples of the growths will be collected after the second treatment; this will be done
under general anesthesia.
Participants may undergo apheresis: Blood will be drawn from a needle in an arm. The blood
will pass through a machine that separates out the cells needed for the study. The remaining
blood will be returned to the body through a second needle.
Follow-up will continue for 1 year after the last treatment.